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Ectopic expression of PU.1, IRF8, and BATF3 reprograms mouse and human fibroblasts 
into dendritic cells. See related Research Article by Rosa et al  .  
In this issue of Science Immunology, Rosa et al. describe a strategy to reprogram fibroblasts 
into dendritic cells (DCs) (1  ). DCs play a central role in shaping adaptive immune responses 
and in the generation of immune memory. Upon activation, DCs up-regulate costimulatory 
molecules and chemokine receptors that allow their migration to draining lymph nodes 
(migratory DC), where they interact with antigen-specific T cells. It is now appreciated that 
DCs are functionally heterogeneous. Broadly, DCs have been classified into plasmacytoid DCs 
(pDCs) and conventional DCs (cDCs). pDCs are potent producers of type 1 interferons that 
drive immune responses in the context of viral infection. cDCs have been further 
subclassified into cDC1s and cDC2s (2  ). cDC1s induce activation of cytotoxic T cell 
responses through cytosolic antigen presentation or crosspresentation of exogenous 
antigens via class  I  major  histocompatibility  complex  (MHCI)  molecules.  cDC2s  are  
functionally more diverse, equipped with a broad range of pattern recognition receptors, and 
specialized in the presentation of extracellular antigens via the MHCII pathway to induce CD4+
T cell responses.  
One challenge in studying DCs or harnessing their potential for clinical intervention to target 
the adaptive immune response against antigens of choice is that they are relatively rare 
immune cells, and the generation of DCs in large numbers remains a challenge. In the early 
1990s, it was shown that the culture of mouse bone marrow (BM) cells or human peripheral 
blood mononuclear cells with granulocyte/macrophagestimulating factor (GM-CSF), in 
combination with interleukin-4 (IL-4), generated cells with DC-like characteristics, including a 
typical dendritic morphology, membrane expression of CD11c, and MHCII molecules and the 
capacity to activate naiv̈e allogeneic T cells (3  , 4  ). However, as our appreciation of DC 
heterogeneity advanced, it became apparent that DCs generated by using these culture 
conditions are, for the most part, descendants of monocytes, which are now termed 
monocyte-derived DCs (moDCs). moDCs show some in vivo similarities to migratory DCs and 
cDC2s but not to cDC1s (5  ). Indeed, cDCs are derived from a dedicated DC precursor in the 
BM and do not share a monocyte origin. Therefore, several questions arise from these results. 
How appropriate would it be to use moDCs as surrogates for cDCs? Are these moDCs efficient 
inducers of CD8+ T cell responses in vivo, and can this lead to a long-lasting immune memory? 
Have these moDCs acquired all the migratory, secretory, and antigen-presenting machinery 
that cDCs have? More recently, it has become feasible to generate cDC1-like cells by using 
culture systems that involve addition of FMS-like tyrosine kinase 3 ligand (FLT3L) and the 
Notch2 ligand δ-like protein 1 (DLL1/DL1) (6  , 7  ). FLT3L is essential for cDC development in 
both human and mouse, and  the  absence  of  this  cytokine  leads  to  strong  reduction in 
the number of cDCs but not monocytes. Although FLT3L/ DLL1-derived cDC1-like cells show 
stronger correlation to their in vivo counterparts, the generation of these cells for effective 
therapy would require large numbers of autologous BM stem cells or BM cDC precursors. 
Another possibility is the generation of DCs from induced-pluripotent stem cells (iPSCs). To 
date, attempts to generate DCs from iPSCs remain in their infancy. 
Rosa et al. have used an alternative approach to reprogram fibroblasts directly into cDC-like 
cells (1  ). The authors investigated the ability of a set of candidate transcription factors to 
induce cDC-like cells directly from fibroblasts. They initially screened 18 transcription factors 
that are enriched in the DC lineage and tested their potential to induce reporter expression in 
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embryonic fibroblasts isolated from Clec9a-Cre X R26-stop-tdTomato mice (8). Clec9a has 
been previously shown to be specifically expressed by cDC1 and, to a lesser extent, by cDC2 
cells but not by other hematopoietic cells. This allowed the authors to use Clec9a reporter 
expression as a surrogate for the reprogramming of fibroblasts into cDCs. By combining 
smaller sets of transcription factors together, the authors identified three transcription 
factors, PU.1, IRF8, and BATF3, to be sufficient to directly reprogram mouse and human 
endothelial fibroblasts into cDC1-like cells that the authors have termed “induced” DCs 
(iDCs). Previous studies in mice have shown that both IRF8 and BATF3 are vital for the 
generation of cDC1 because the deletion of either gene leads to the almost complete 
absence of cDC1 cells in vivo (9, 10). 
Although the authors were able to reprogram mouse embryonic fibroblasts, human 
embryonic fibroblasts, and human dermal fibroblasts to iDCs, the authors chose to carry out 
much of the in-depth analyses on mouse embryonic fibroblast–derived iDCs. Mouse iDCs 
exhibited a stellate morphology and high surface expression of MHCII and MHCI molecules and 
could be activated by TLR3 (polyinosinic:polycytidylic acid) or TLR4 (lipopolysaccharide) 
ligands. The authors also examined the ability of mouse iDCs to present antigen to induce a 
robust CD4+ T cell response and, more  importantly,  to  prime  CD8+ T cells responses by 
means of cross-presentation. As for human iDCs, the authors confirmed that these iDCs had 
cDC1-like characteristics, with phagocytic activity and MHCII (human lymphocyte antigen–DR) 
expression.  
By carrying out single-cell RNA sequencing from iDCs on days 3, 7, and 9 of 
transdifferentiation, the authors explored the relationships between PU.1, IRF8, and BATF3 in 
shaping the transcriptional program in iDCs. The authors found that transdifferentiation 
followed an asynchronous and stepwise program that terminates in stable commitment to 
the DC fate through the induction of endogenous Irf8 and Batf3 expression. 
The author’s transdifferentiation system to generate DCs is likely to be valuable in basic 
research and in the clinic. In terms of DC biology, this system should allow further in-depth 
exploration of underlying epigenetic events during DC differentiation in both humans and 
mice. Because skin fibroblasts from patients are relatively easy to obtain, it is conceivable 
that this system could become important in the clinic to generate autologous, patient-
specific iDCs for vaccines.  
However, much remains to be learned about this PU.1-, IRF8-, and BATF3-dependent 
reprogramming. First and foremost, the stability of these cells in vivo and their antigen 
presentation abilities under pathological conditions remains to be examined. Whether injected 
iDCs can traffic to lymphoid organs and interact with immune and nonimmune cells in these 
organs remains to be seen. For clinical applications in which large numbers of autologous DCs 
are required, a direct comparison to FLT3L/DLL1-derived cDC1-like cells with respect to cell 
yield and costs is needed. Nonetheless, what is most exciting about the system developed by 
Rosa et al. is that it could be tweaked to generate subsets of DCs other than cDC1s. By 
generating DCs from fibroblasts, Rosa et al. have opened up the avenue of cellular 
reprogramming for the next generation of cellular vaccines.  
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Fig. 1.The reprogramming of fibroblasts into induceddendritic cells. Using transgenic mouse embryonic fibro-blast 
cells that express a Cre recombinase under the control of the DC-specific gene Clec9a, Rosa etal. dis-covered that 
ectopic expression of three transcription factors, PU.1 (encoded by Spi1), IRF8, and BATF3 could directly reprogram 
mouse and human fibroblasts into cDC1-like cells. After successful transdifferentiation and the induction of 
endogenous Clec9a expression, induced DCs (iDCs) are characterized through tomato reporter gene activation, thus 
allowing their identification. iDC exhibited a stellate morphology and a transcription program similar to cDC1 and can 
present antigen to induce both a CD4+ and CD8+ T cell response.
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